PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.

被引：0
|
作者：
Poggio, Francesca
Bruzzone, Marco
Ceppi, Marcello
Conte, Benedetta
Martel, Samuel
Maurer, Christian
Tagliamento, Marco
Viglietti, Giulia
Del Mastro, Lucia
De Azambuja, Evandro
Lambertini, Matteo
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med Oncol, Brussels, Belgium
[2] Osped Policli San Martino, Clin Epidemiol Unit, Genoa, Italy
[3] Osped Policlin San Martino, Oncol Med 2, Dept Med Oncol, Genoa, Italy
[4] CHU Sherbrooke, Hop Fleurimont, Sherbrooke, PQ, Canada
[5] Univ Cologne, Dept Internal Med, German CLL Study Grp, Cologne, Germany
[6] Univ Cologne, German CLL Study Grp, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany
[7] Osped Policlin San Martino, Lung Canc Unit, Genoa, Italy
[8] Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium
[9] IRCCS AOU San Martino IST, Med Oncol, Genoa, Italy
[10] Inst Jules Bordet, Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13098
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Poggio, Francesca
    Bruzzone, Marco
    Ceppi, Marcello
    Conte, Benedetta
    Martel, Samuel
    Maurer, Christian
    Tagliamento, Marco
    Viglietti, Giulia
    Del Mastro, Lucia
    de Azambuja, Evandro
    Lambertini, Matteo
    [J]. ESMO OPEN, 2018, 3 (04)
  • [2] Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis
    Sun, Wanyi
    Wu, Yun
    Ma, Fei
    Fan, Jinhu
    Qiao, Youlin
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [3] BRCA testing and PARP inhibitor utilization in real-world HER2negative metastatic breast cancer
    Yadav, Siddhartha
    Hillman, Sam
    Luo, Linlin
    Li, Weiyan
    Earla, Jagadeswara
    Xu, Xiaoqing
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [4] Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer
    Spring, L. M.
    Han, H.
    Hamilton, E.
    Irie, H.
    Santa-Maria, C. A.
    Reeves, J.
    Pan, P.
    Shan, M.
    Tang, Y.
    Graham, J. R.
    Hazard, S.
    Ellisen, L. W.
    Isakoff, S. J.
    [J]. BREAST, 2021, 56 : S55 - S56
  • [5] Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review
    Sun, Ximu
    Wang, Xin
    Zhang, Jie
    Zhao, Zhixia
    Feng, Xin
    Liu, Lihong
    Ma, Zhuo
    [J]. BREAST, 2021, 60 : 26 - 34
  • [6] Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer
    McCrea, Charles
    Hettle, Robert
    Gulati, Poonam
    Taneja, Ankush
    Rajora, Preety
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) : 1021 - 1030
  • [7] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
    Spring, Laura M.
    Han, Hyo
    Liu, Minetta C.
    Hamilton, Erika
    Irie, Hanna
    Santa-Maria, Cesar A.
    Reeves, James
    Pan, Peng
    Shan, Ming
    Tang, Yongqiang
    Graham, Julie R.
    Hazard, Sebastien
    Ellisen, Leif W.
    Isakoff, Steven J.
    [J]. NATURE CANCER, 2022, 3 (08) : 927 - +
  • [8] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
    Laura M. Spring
    Hyo Han
    Minetta C. Liu
    Erika Hamilton
    Hanna Irie
    Cesar A. Santa-Maria
    James Reeves
    Peng Pan
    Ming Shan
    Yongqiang Tang
    Julie R. Graham
    Sebastien Hazard
    Leif W. Ellisen
    Steven J. Isakoff
    [J]. Nature Cancer, 2022, 3 : 927 - 931
  • [9] Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis
    Dacoregio, Maria Inez
    Vilbert, Maysa
    Stecca, Carlos
    Michelon, Isabella
    Castro, Caio
    Amir, Eitan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis
    Tomasello, G.
    Gambini, D.
    Petrelli, F.
    Azzollini, J.
    Arcana, C.
    Ghidini, M.
    Peissel, B.
    Manoukian, S.
    Garrone, O.
    [J]. ESMO OPEN, 2022, 7 (04)
12345